Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy
Autore:
van Ojik, HH; Valerius, T;
Indirizzi:
Univ Erlangen Nurnberg, Dept Med 3, Div Hematol Oncol, D-91054 Erlangen, Germany Univ Erlangen Nurnberg Erlangen Germany D-91054 -91054 Erlangen, Germany Univ Utrecht, Med Ctr, Immunotherapy Lab, Dept Immunol, Utrecht, Netherlands Univ Utrecht Utrecht Netherlands ab, Dept Immunol, Utrecht, Netherlands Univ Utrecht, Med Ctr, Immunotherapy Lab, Dept Internal Med, Utrecht, Netherlands Univ Utrecht Utrecht Netherlands ept Internal Med, Utrecht, Netherlands
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 1, volume: 38, anno: 2001,
pagine: 47 - 61
SICI:
1040-8428(200104)38:1<47:PACDWB>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; FC-GAMMA-RI; METASTATIC BREAST-CANCER; HIGH-AFFINITY RECEPTOR; NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODY; B-CELL; ALPHA-RI; IN-VIVO; T-CELL;
Keywords:
bispecific antibody; tumor therapy; neutrophils; monocytes; macrophages; growth factor;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
139
Recensione:
Indirizzi per estratti:
Indirizzo: Valerius, T Univ Erlangen Nurnberg, Dept Med 3, Div Hematol Oncol, Krankenhausstr 12, D-91054 Erlangen, Germany Univ Erlangen Nurnberg Krankenhausstr12 Erlangen Germany D-91054
Citazione:
H.H. van Ojik e T. Valerius, "Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy", CR R ONC H, 38(1), 2001, pp. 47-61

Abstract

Bispecific antibodies constitute a novel approach to improve antibody efficacy. In vitro, constructs to recruit myeloid effector cells have been extensively investigated, and first animal data in human Fc receptor transgenicmice confirmed their promising therapeutic potential. Clinical experience with these constructs demonstrated acceptable toxicity, and support therapeutic efficacy in subgroups of patients. However, limited availability. unacceptable immunogenicity, and unfavorable pharmacokinetics of bispecific compared to conventional antibodies often hampered clinical studies. As solutions to these problems are available today, bispecific antibodies hold promise to improve therapeutic efficacy of antibody-based approaches in the nearfuture. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:34:35